[HTML][HTML] Human African trypanosomiasis of the CNS: current issues and challenges
PGE Kennedy - The Journal of clinical investigation, 2004 - Am Soc Clin Investig
The Journal of clinical investigation, 2004•Am Soc Clin Investig
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a major cause of
mortality and morbidity in sub-Saharan Africa. Current therapy with melarsoprol for CNS
HAT has unacceptable side-effects with an overall mortality of 5%. This review discusses the
issues of diagnosis and staging of CNS disease, its neuropathogenesis, and the possibility
of new therapies for treating late-stage disease.
mortality and morbidity in sub-Saharan Africa. Current therapy with melarsoprol for CNS
HAT has unacceptable side-effects with an overall mortality of 5%. This review discusses the
issues of diagnosis and staging of CNS disease, its neuropathogenesis, and the possibility
of new therapies for treating late-stage disease.
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a major cause of mortality and morbidity in sub-Saharan Africa. Current therapy with melarsoprol for CNS HAT has unacceptable side-effects with an overall mortality of 5%. This review discusses the issues of diagnosis and staging of CNS disease, its neuropathogenesis, and the possibility of new therapies for treating late-stage disease.
The Journal of Clinical Investigation